Patents by Inventor Nathalie Mondoly

Nathalie Mondoly has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Therapeutical composition containing apomorphine as active ingredient
    Patent number: 11766431
    Abstract: A pharmaceutical composition contains apomorphine as the active pharmaceutical ingredient, a water-miscible co-solvent, an antioxidant, and water. The solution has a pH greater than 4. The pharmaceutical composition is suitable for parenteral administration for the treatment of Parkinson's disease. The process for the manufacture of the pharmaceutical composition includes weighing the apomorphine and introducing it into a container with the co-solvent and the antioxidant under agitation until complete dissolution takes place.
    Type: Grant
    Filed: April 30, 2021
    Date of Patent: September 26, 2023
    Assignee: Britannia Pharmaceuticals Ltd.
    Inventors: Michael Dey, Joel Richard, Marie-Madeleine Baronnet, Nathalie Mondoly, Laurent Bertocchi, Jeremiah Harnett
  • NEW THERAPEUTICAL COMPOSITION CONTAINING APOMORPHINE AS ACTIVE INGREDIENT
    Publication number: 20210244724
    Abstract: A pharmaceutical composition contains apomorphine as the active pharmaceutical ingredient, a water-miscible co-solvent, an antioxidant, and water. The solution has a pH greater than 4. The pharmaceutical composition is suitable for parenteral administration for the treatment of Parkinson's disease. The process for the manufacture of the pharmaceutical composition includes weighing the apomorphine and introducing it into a container with the co-solvent and the antioxidant under agitation until complete dissolution takes place.
    Type: Application
    Filed: April 30, 2021
    Publication date: August 12, 2021
    Inventors: Michael Dey, Joel Richard, Marie-Madeleine Baronnet, Nathalie Mondoly, Laurent Bertocchi, Jeremiah Harnett
  • Therapeutical composition containing apomorphine as active ingredient
    Patent number: 11026938
    Abstract: A pharmaceutical composition contains apomorphine as the active pharmaceutical ingredient, a water-miscible co-solvent, an antioxidant, and water. The solution has a pH greater than 4. The pharmaceutical composition is suitable for parenteral administration for the treatment of Parkinson's disease. The process for the manufacture of the pharmaceutical composition includes weighing the apomorphine and introducing it into a container with the co-solvent and the antioxidant under agitation until complete dissolution takes place.
    Type: Grant
    Filed: January 10, 2014
    Date of Patent: June 8, 2021
    Assignee: Britannia Pharmaceuticals Ltd.
    Inventors: Michael Dey, Joel Richard, Marie-Madeleine Baronnet, Nathalie Mondoly, Laurent Bertocchi, Jeremiah Harnett
  • THERAPEUTICAL COMPOSITION CONTAINING APOMORPHINE AS ACTIVE INGREDIENT
    Publication number: 20180098981
    Abstract: A pharmaceutical composition contains apomorphine as the active pharmaceutical ingredient, a water-miscible co-solvent, an antioxidant, and water. The solution has a pH greater than 4. The pharmaceutical composition is suitable for parenteral administration for the treatment of Parkinson's disease. The process for the manufacture of the pharmaceutical composition includes weighing the apomorphine and introducing it into a container with the co-solvent and the antioxidant under agitation until complete dissolution takes place.
    Type: Application
    Filed: December 13, 2017
    Publication date: April 12, 2018
    Applicant: BRITANNIA PHARMACEUTICALS LTD.
    Inventors: Michael DEY, Joel RICHARD, Marie-Madeleine BARONNET, Nathalie MONDOLY, Laurent BERTOCCHI, Jeremiah HARNETT
  • AQUEOUS GELLING COMPOSITIONS OF SOLUBLE ACTIVE PHARMACEUTICAL PEPTIDES PROVIDING MODIFIED RELEASE
    Publication number: 20170035884
    Abstract: An aqueous pharmaceutical composition comprising a peptide and one or more water-soluble or water-dispersible gelling agents.
    Type: Application
    Filed: September 22, 2016
    Publication date: February 9, 2017
    Inventors: Marie-Madeleine Baronnet, Joël Richard, Nathalie Mondoly, Didier Nourrisson
  • Clay compositions
    Patent number: 9511023
    Abstract: The present invention relates to liquid or semi-solid pharmaceutical compositions, more specifically to aqueous pharmaceutical suspension or semi-solid paste containing natural mineral clays as active ingredients. These compositions are particularly useful for the treatment of acute and chronic diarrhea.
    Type: Grant
    Filed: April 29, 2011
    Date of Patent: December 6, 2016
    Assignee: IPSEN PHARMA S.A.S.
    Inventors: Béatrice Hacher, Didier Kubiak, Jeremiah Harnett, Nathalie Mondoly
  • THERAPEUTICAL COMPOSITION CONTAINING APOMORPHINE AS ACTIVE INGREDIENT
    Publication number: 20160310480
    Abstract: A pharmaceutical composition contains apomorphine as the active pharmaceutical ingredient, a water-miscible co-solvent, an antioxidant, and water. The solution has a pH greater than 4. The pharmaceutical composition is suitable for parenteral administration for the treatment of Parkinson's disease. The process for the manufacture of the pharmaceutical composition includes weighing the apomorphine and introducing it into a container with the co-solvent and the antioxidant under agitation until complete dissolution takes place.
    Type: Application
    Filed: June 30, 2016
    Publication date: October 27, 2016
    Inventors: Michael Dey, Joel Richard, Marie-Madeleine Baronnet, Nathalie Mondoly, Laurent Bertocchi, Jeremiah Harnett
  • Sustained-release composition containing peptides as active ingredient
    Patent number: 9415012
    Abstract: The present invention relates to a sustained-release drug composition consisting essentially of microparticles of a peptide as the active substance and a biocompatible water-soluble polymer, in particular peptide as meianocortin receptor ligand. The present invention relates also to an injection formulation comprising the sustained-release drug composition suspended in an injection medium.
    Type: Grant
    Filed: June 13, 2012
    Date of Patent: August 16, 2016
    Assignee: IPSEN PHARMA S.A.S.
    Inventors: Joël Richard, Faïza Laredj, Marie-Madeleine Baronnet, Didier Nourrisson, Jeremiah Harnett, Béatrice Hacher, Nathalie Mondoly, Laurent Bertocchi
  • Aqueous Gelling Compositions of Soluble Active Pharmaceutical Peptides Providing Modified Release
    Publication number: 20150157719
    Abstract: The present invention relates to an aqueous pharmaceutical composition comprising a peptide as the active ingredient, and one or more water-soluble or water-dispersible gelling agents.
    Type: Application
    Filed: June 13, 2013
    Publication date: June 11, 2015
    Inventors: Marie-Madeleine Baronnet, Joël Richard, Nathalie Mondoly, Didier Nourrisson
  • Method of drug delivery for bone anabolic protein
    Patent number: 8748382
    Abstract: The present invention provides a storage-stable composition containing a parathyroid hormone-related protein (PTHrP) and methods of using a PTHrP and the PTHrP compositions described herein to treat osteoporosis, to increase bone mass or to increase bone quality. The composition is storage stable, in sterile form, and in general may be stored at room temperature for at least several weeks to allow convenient parenteral administration to human patients.
    Type: Grant
    Filed: April 3, 2012
    Date of Patent: June 10, 2014
    Assignees: Radius Health, Inc., Ipsen Pharma S.A.S.
    Inventors: Michael J. Dey, Nathalie Mondoly, Benedicte Rigaud, Bart Henderson, C. Richard Lyttle
  • NEW THERAPEUTICAL COMPOSITION CONTAINING APOMORPHINE AS ACTIVE INGREDIENT
    Publication number: 20140128422
    Abstract: A pharmaceutical composition contains apomorphine as the active pharmaceutical ingredient, a water-miscible co-solvent, an antioxidant, and water. The solution has a pH greater than 4. The pharmaceutical composition is suitable for parenteral administration for the treatment of Parkinson's disease. The process for the manufacture of the pharmaceutical composition includes weighing the apomorphine and introducing it into a container with the co-solvent and the antioxidant under agitation until complete dissolution takes place.
    Type: Application
    Filed: January 10, 2014
    Publication date: May 8, 2014
    Applicant: Britannia Pharmaceuticals Ltd.
    Inventors: Michael Dey, Joel Richard, Marie-Madeleine Baronnet, Nathalie Mondoly, Laurent Bertocchi, Jeremiah Harnett
  • SUSTAINED-RELEASE COMPOSITION CONTAINING PEPTIDES AS ACTIVE INGREDIENT
    Publication number: 20140127303
    Abstract: The present invention relates to a sustained-release drug composition consisting essentially of microparticles of a peptide as the active substance and a biocompatible water-soluble polymer, in particular peptide as meianocortin receptor ligand. The present invention relates also to an injection formulation comprising the sustained-release drug composition suspended in an injection medium.
    Type: Application
    Filed: June 13, 2012
    Publication date: May 8, 2014
    Applicant: IPSEN PHARMA S.S.A.
    Inventors: Joël Richard, Faïza Laredj, Maire-Madeleine Baronnet, Didier Nourrisson, Jeremiah Harnett, Béatrice Hacher, Nathalie Mondoly, Laurent Bertocchi
  • SOLID PHARMACEUTICAL COMPOSITION CONTAINING 6-OXO-6,7,8,9,10,11-HEXAHYDROCYCLOHEPTA (C)CHROMEN-3-YL SULFAMATE AND POLYMORPHS THEREOF
    Publication number: 20140056977
    Abstract: The present invention relates to a solid pharmaceutical composition including the active principle 6-oxo-6,7,8,9,10,11-hexahydrocyclohepta[c]chromen-3-yl sulfamate. The present invention also relates to polymorphs of the 6-oxo-6,7,8,9,10,11-hexahydrocyclohepta[c]chromen-3-yl sulfamate compound.
    Type: Application
    Filed: August 1, 2013
    Publication date: February 27, 2014
    Applicant: Ipsen Pharma S.A.S.
    Inventors: Nathalie MONDOLY, Bertrand Poirot, Anne Brochard, Joël Richard, Delphine Delahaye, Christian Diolez, Alain Rolland, Francis Diancourt, Gérard Coquerel, Damien Martins, Julie Linol, Ophélie Houssin, Marie-Noêlle Petit, Barry, Victor, Lloyd Potter, Lok, Wai Lawrence Woo
  • METHOD OF DRUG DELIVERY FOR BONE ANABOLIC PROTEIN
    Publication number: 20130157955
    Abstract: The present invention provides a storage-stable composition containing a parathyroid hormone-related protein (PTHrP) and methods of using a PTHrP and the PTHrP compositions described herein to treat osteoporosis, to increase bone mass or to increase bone quality. The composition is storage stable, in sterile form, and in general may be stored at room temperature for at least several weeks to allow convenient parenteral administration to human patients.
    Type: Application
    Filed: April 3, 2012
    Publication date: June 20, 2013
    Applicants: Ipsen Pharma S.A.S., Radius Health, Inc.
    Inventors: Michael J. Dey, Nathalie Mondoly, Benedicte Rigaud, Bart Henderson, C. Richard Lyttle
  • CLAY COMPOSITIONS
    Publication number: 20130059016
    Abstract: The present invention relates to liquid or semi-solid pharmaceutical compositions, more specifically to aqueous pharmaceutical suspension or semi-solid paste containing natural mineral clays as active ingredients. These compositions are particularly useful for the treatment of acute and chronic diarrhea.
    Type: Application
    Filed: April 29, 2011
    Publication date: March 7, 2013
    Applicant: Ipsen Pharma S.A.S
    Inventors: Béatrice Hacher, Didier Kubiak, Jeremiah Harnett, Nathalie Mondoly
  • SOLID PHARMACEUTICAL COMPOSITION CONTAINING 6-OXO-6,7,8,9,10,11-HEXAHYDROCYCLOHEPTA (C)CHROMEN-3-YL SULFAMATE AND POLYMORPHS THEREOF
    Publication number: 20120321714
    Abstract: The present invention relates to a solid pharmaceutical composition including the active principle 6-oxo-6,7,8,9,10,11-hexahydrocyclohepta[c]chromen-3-yl sulfamate. The present invention also relates to polymorphs of the 6-oxo-6,7,8,9,10,11-hexahydrocyclohepta[c]chromen-3-yl sulfamate compound.
    Type: Application
    Filed: March 26, 2012
    Publication date: December 20, 2012
    Applicant: Ipsen Pharma S.A.S.
    Inventors: Nathalie MONDOLY, Bertrand Poirot, Anne Brochard, Joël Richard, Delphine Delahaye, Christian Diolez, Alain Rolland, Francis Diancourt, Gérard Coquerel, Damien Martins, Julie Linol, Marie-Noêlle Petit, Barry Victor Llyod Potter, Lok, Wai Lawrence Woo
  • Stable composition comprising a PTHrP analogue
    Patent number: 8148333
    Abstract: The present invention provides a storage-stable composition containing a parathyroid hormone-related protein (PTHrP) analogue and methods of using a PTHrP analogue and the PTHrP compositions described herein to treat osteoporosis, to increase bone mass or to increase bone quality. The composition is storage stable, in sterile form, and in general may be stored at room temperature for at least several weeks to allow convenient parenteral administration to human patients.
    Type: Grant
    Filed: October 3, 2007
    Date of Patent: April 3, 2012
    Assignees: Radius Health, Inc., Ipsen Pharma S.A.S.
    Inventors: Michael J. Dey, Nathalie Mondoly, Benedicte Rigaud, Bart Henderson, C. Richard Lyttle
  • GLP-1 ANALOGUES PHARMACEUTICAL COMPOSITIONS
    Publication number: 20120077746
    Abstract: The present invention is directed to sustained release liquid pharmaceutical compositions comprising a liquid, a peptide analogue according to the formula [Aib8,35]hGLP-1 (7-36)NH2, a divalent metal and/or divalent metal salt, and an acetate salt and/or acetic acid. The invention also relates to containers comprising the pharmaceutical compositions and methods for preparing the pharmaceutical compositions.
    Type: Application
    Filed: February 8, 2010
    Publication date: March 29, 2012
    Applicant: Ipsen Pharma S.A.S.
    Inventors: Nathalie Mondoly, Anne Brochard
  • METHOD OF DRUG DELIVERY FOR BONE ANABOLIC PROTEIN
    Publication number: 20110092425
    Abstract: The present invention provides a storage-stable composition containing a parathyroid hormone-related protein (PTHrP) and methods of using a PTHrP and the PTHrP compositions described herein to treat osteoporosis, to increase bone mass or to increase bone quality. The composition is storage stable, in sterile form, and in general may be stored at room temperature for at least several weeks to allow convenient parenteral administration to human patients.
    Type: Application
    Filed: August 12, 2010
    Publication date: April 21, 2011
    Applicants: Radius Health, Inc., Ipsen Pharma S.A.S
    Inventors: Michael J. Dey, Nathalie Mondoly, Benedicte Rigaud, Bart Henderson, C. Richard Lyttle
  • Method of treating osteoporosis comprising administration of PTHrP analog
    Patent number: RE49444
    Abstract: The present invention provides a storage-stable composition containing a parathyroid hormone-related protein (PTHrP) and methods of using a PTHrP and the PTHrP compositions described herein to treat osteoporosis, to increase bone mass or to increase bone quality. The composition is storage stable, in sterile form, and in general may be stored at room temperature for at least several weeks to allow convenient parenteral administration to human patients.
    Type: Grant
    Filed: December 24, 2020
    Date of Patent: March 7, 2023
    Assignees: Radius Health, Inc., Ipsen Pharma S.A.S.
    Inventors: Michael J. Dey, Nathalie Mondoly, Benedicte Rigaud, Bart Henderson, C. Richard Lyttle, Zhengxin Dong